We shape the world of 

AI-Blood Diagnostics

Our Mission

AiMorphous Health is a Swiss Medtech startup. We are at the forefront of innovation, spearheading the development of a disruptive AI-powered blood diagnostics engineered to predict the risks of thrombosis and bleeding, potentially safeguarding the lives of numerous patients.

 

Thrombosis 

 
  • Thrombosis is a leading cause of heart attacks, strokes, vein thrombosis, or lung emboli, accounting for over 25% of deaths globally.
  • Research indicates that a staggering 80% of thrombosis cases could be prevented through early detection.
  • Unfortunately, there is currently no reliable test capable of identifying the risk of early or asymptomatic thrombosis.
  • But that is about to change! We are developing a groundbreaking blood test designed to identify early biomarkers of thrombosis.
  • Our AI-powered blood diagnostics leverage advanced algorithms and machine learning models to analyze blood samples with unprecedented accuracy and precision. By identifying subtle patterns and anomalies that may elude traditional diagnostic methods, these systems can provide earlier detection of a wide range of health issues, from chronic diseases to emerging conditions.
  • This breakthrough has the potential to enable timely intervention and treatment, preventing thrombosis from escalating into life-threatening events.
  • By detecting thrombosis risk early, we can save countless lives and reduce the burden of these devastating cardiovascular conditions on individuals and society.
  • This innovative solution represents a significant step forward in thrombosis prevention and management, offering hope for a healthier future.

 

 

 
 
 

Supports and Recognition

 

We're all about people

Dr. San Pun

Founder & CEO

Daniel Shoukier

Co-Founder & CTO

News

June 12, 2024 (London) –

MassChallenge UK, a key player in MassChallenge's global network of innovators, has unveiled the 18 early-stage startups selected for its 2024 accelerator program, featuring AiMorphous Health among the cohort.

The selected startups represent the top 10% of applications we received from around the world. They were judged by over 35 independent experts from the MassChallenge Community, who gave feedback to each of the startups to help them improve their propositions. 

 

 https://masschallenge.org/news/masschallenge-uk-2024-early-stage-accelerator-cohort/#:~:text=MassChallenge%20UK%20Startups%202024:%20AiMorphous%20Health%20(United%20Kingdom):%20AH%20develops

Impressum

AiMorphous Health AG

 

Place des Sciences 2

2822 Courroux

Switzerland

 

Dr. San Pun - CEO

 

E-mail: info@aimorphous.com